

DECIPHER BLADDER PUBLICATIONS

Jäger, W., Xue, H., Hayashi, T., Janssen, C., Awrey, S., Wyatt, A. W., ... Black, P. C. (2015). Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. *Oncotarget*, 6(25). <https://doi.org/10.18632/oncotarget.3974>

Kiss, B., Wyatt, A. W., Douglas, J., Skuginna, V., Mo, F., Anderson, S., ... Seiler, R. (2017). Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. *Scientific Reports*, 7. <https://doi.org/10.1038/srep42713>

Mitra, A. P., Lam, L. L., Ghadessi, M., Erho, N., Vergara, I. a, Alshalalfa, M., ... Black, P. C. (2014). Discovery and Validation of a Novel Expression Signature for Recurrence in High-Risk Bladder Cancer Post-Cystectomy. *Journal of the National Cancer Institute*, 1–9. <https://doi.org/10.1093/jnci/dju290>

Seiler, R., Ashab, H. A. D., Erho, N., van Rhijn, B. W. G., Winters, B., Douglas, J., ... Black, P. C. (2017). Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy [Figure presented]. *European Urology*, 72(4), 544–554. <https://doi.org/10.1016/j.eururo.2017.03.030>

Seiler, R., Choi, W., Lam, L. L. C., Erho, N., Buerki, C., Davicioni, E., ... Black, P. C. (2015). Association of p53-ness with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin. *ASCO Meeting Abstracts*, 33(15_suppl), 4512. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4512

Seiler, R., Gibb, E. A., Wang, N. Q., Oo, H. Z., Lam, H.-M., Van Kessel, K. E., ... Black, P. C. (2018). Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. *Clinical Cancer Research*, clincanres.1106.2018. <https://doi.org/10.1158/1078-0432.CCR-18-1106>

Seiler, R., Lam, L. L. C., Erho, N., Davicioni, E., Mitra, A. P., Skinner, E. C., ... Black, P. C. (2015). Can bladder cancer gene expression signatures be used to predict lymph node metastasis at the time of radical cystectomy? *Journal of Urology*. <https://doi.org/10.1016/j.juro.2015.02.2416>

Seiler, R., Lam, L. L., Erho, N., Takhar, M., Mitra, A. P., Buerki, C., ... Black, P. C. (2016). Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. *Journal of Urology*, 196(4), 1036–1041. <https://doi.org/10.1016/j.juro.2016.04.061>

Seiler, R., Oo, H. Z., Tortora, D., Clausen, T. M., Wang, C. K., Kumar, G., ... Daugaard, M. (2017). An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. *European Urology*, 72(1), 142–150. <https://doi.org/10.1016/j.eururo.2017.03.021>